Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
CAMP4 Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Study of CMP-CPS-001, a Potential First-in-Class Therapeutic for Urea Cycle Disorders
Read Article
News
2024
2023
Archive
Search news articles
April 1, 2021
Pear Therapeutics and Prescryptive Health Announce Formulary Coverage for Prescription Digital Therapeutics reSET® and reSET-O® for the Treatment of Substance and Opioid Use Disorders
March 31, 2021
Entrada Therapeutics Announces Closing of $116 Million Series B Financing
March 30, 2021
TMRW Life Sciences Appoints Tara Comonte as Chief Executive Officer
March 23, 2021
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity
March 16, 2021
Tufts Health Plan, New England Recovery Center, a Subsidiary of Spectrum Health Systems, and Pear Therapeutics Team Up to Support Members in Recovery from Substance Use Disorder
March 11, 2021
Nouscom Receives Approval to Begin Phase 1B Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy
March 9, 2021
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China Region
March 2, 2021
Rallybio Reveals Details of Two Pipeline Programs with the Potential to Transform the Lives of Patients with Rare Diseases
March 2, 2021
Impel Neuropharma Announces Key Management Team Appointments as Company Advances Toward Commercialization in 2021
March 1, 2021
Homology Medicines Regains Worldwide Rights to Ophthalmology Program Based on its In Vivo Nuclease-Free Gene Editing Platform
« Previous Page
1
…
26
27
28
29
30
…
103